Lantern Pharma to outline Open-Medicine AI growth plan
The scheduled 45-minute session includes a live demonstration and Q&A alongside discussion of platform economics, benchmarks, and partnerships under discussion.
Rhea-AI Filing Summary
Lantern Pharma Inc. (LTRN) is scheduled to present the growth plan for its wholly owned Open-Medicine AI subsidiary at a live webinar on September 23, 2026, at 12:30 PM Eastern. The 45-minute session is described as including a presentation, live demonstration, and Q&A, with discussion of market opportunity, customer feedback, roadmap, subscription and enterprise licensing economics, benchmarks, and partnerships under discussion.
Open-Medicine AI’s platform was first commercialized as withZeta.ai in April 2026 for rare and aggressive cancers; ZetaOmics, a computational biology module, was released to early-access users in July 2026. The company says it is extending the platform to additional disease categories, therapeutic modalities, and stages of drug development.
Positive
- None.
Negative
- None.
8-K Event Classification
Key Figures
Key Terms
multi-agentic AI platform technical
enterprise licensing financial
computational biology module technical
translational analysis technical
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What is Lantern Pharma (LTRN) announcing about Open-Medicine AI?
When is the Lantern Pharma (LTRN) Open-Medicine AI webinar?
What is Open-Medicine AI and how is it offered?
What milestones has Lantern Pharma’s Open-Medicine AI platform reached?
AI-generated analysis. How Rhea-AI works. Not financial advice.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
(State or Other Jurisdiction of Incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
| (Address of Principal Executive Offices) | (Zip Code) |
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act: Common Stock
| Title of each class | Trading Symbol | Name of each exchange on which registered | ||
| The
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 7.01 Regulation FD Disclosure.
On September 23, 2026, Lantern Pharma Inc. (the “Company”) will issue a press release describing topics to be covered during a live webinar hosted by the Company on September 23, 2026 to discuss Open-Medicine AI, a multi-agentic AI platform for drug development. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
The information in this Item 7.01, including Exhibit 99.1 hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filings under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filings, unless expressly incorporated by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
| Exhibit No. | Exhibit Description | |
| 99.1 | Press Release dated September 23, 2026 describing topics to be covered during a live webinar hosted by the Company on September 23, 2026 to discuss the Open-Medicine AI platform. | |
| 104 | Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101). |
| 2 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Lantern Pharma Inc., | ||
| A Delaware Corporation | ||
| Dated: September 23, 2026 | By: | /s/ David R. Margrave |
| David R. Margrave, Chief Financial Officer | ||
| 3 |
Exhibit 99.1
Open-Medicine AI: Lantern Pharma to Present the Agentic AI Drug Development Market, User Needs, Development Roadmap, Platform Economics, and Benchmarks, Today at 12:30 PM ET
| ● | Management will also discuss usage patterns, key future milestones, and an overview of the types of collaborations and partnerships under discussion | |
| ● | Investors, collaborators, prospective partners, and interested parties are encouraged to register and see a live demonstration of the platform’s key capabilities: Register Here |
DALLAS — September 23, 2026 — Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage, AI-native biopharma company using artificial intelligence and genomic data to develop precision oncology therapies, will present the growth plan for Open-Medicine AI (OMAI) in a live webinar today at 12:30 PM Eastern. Open Medicine AI is the company’s wholly owned subsidiary building a multi-agentic AI platform for drug development. To register: https://us06web.zoom.us/webinar/register/9417895172347/WN_HNnjzsDuTjufesN-cdwaNw#/registration
CEO Panna Sharma will lead the session and will be joined by the Chief Scientific Officer of Lantern Pharma and the Principal Architect of the multi-agentic platform. OMAI’s core capabilities and initial platform were built inside Lantern’s own clinical programs and areas of focus. The platform launched as withZeta.ai in April 2026, focused on rare cancers, and is now expanding into new diseases, new types of therapies, and additional stages of drug development. Today’s session will show where OMAI is going, share feedback from key user segments, and include a live demonstration of the platform’s most differentiated capabilities.
What the Webinar Will Cover
| ● | Market: The size of the opportunity and the shift from AI pilots to full-scale adoption in drug development. | |
| ● | Customers & Feedback: Who is buying, what they need, how they use the platform; and what key customer segments and power users are telling us. | |
| ● | Live demo: The platform’s differentiated capabilities, shown in real time. | |
| ● | Roadmap: Next generation of functionality and modules, priority disease areas, and key milestones including social and enterprise features. | |
| ● | Economics: The subscription and enterprise licensing model. | |
| ● | Benchmarks: How the platform performs and how performance is being measured. | |
| ● | Partnerships: Types of collaborations and partnerships under discussion. | |
| ● | Shareholder value: How OMAI adds to Lantern’s pipeline and long-term value. |
Upcoming Open-Medicine AI Webinar - www.lanternpharma.com
Webinar Details
| ● | Date and time: Today, Wednesday, September 23, 2026, 12:30 PM Eastern / 9:30 AM Pacific | |
| ● | Register: https://us06web.zoom.us/webinar/register/9417895172347/WN_HNnjzsDuTjufesN-cdwaNw#/registration | |
| ● | Format: 45 minutes, including a presentation and live demo followed by Q&A. Questions can be sent in advance to IR@lanternpharma.com | |
| ● | Replay: Available on the Investors section of www.lanternpharma.com after the event |
About Open Medicine AI
Open Medicine AI is a wholly owned subsidiary of Lantern Pharma that is building a multi-agentic AI platform for end-to-end therapeutic development. Its AI co-scientists were developed inside Lantern’s clinical-stage oncology programs and carry the data, constraints, and decision points of real drug development — from target and biomarker selection through compound design, translational analysis, trial design, and regulatory strategy. The OMAI platform was first commercialized as withZeta.ai, launched in April 2026 for rare and aggressive cancers, and expanded in July 2026 with ZetaOmics™, a computational biology module released to early-access users. OMAI is extending this architecture to additional disease categories, new therapeutic modalities, and the downstream challenges of drug development. The platform is available to biopharma companies, research institutions, service providers, and drug developers through subscription and enterprise licensing. For more information, visit www.open-medicine.ai.
About Lantern Pharma
Lantern Pharma (NASDAQ: LTRN) is a clinical-stage biopharmaceutical company leveraging its proprietary RADR® artificial intelligence and machine-learning platform to transform the cost, pace, and precision of oncology drug development. By integrating large-scale genomic and biological data with advanced machine learning, RADR® is designed to identify the patients most likely to benefit from Lantern’s therapies and to guide biomarker-driven clinical development. The company’s pipeline includes LP-184 (zirdafulven), LP-300, and LP-284, along with its central-nervous-system-focused subsidiary, Starlight Therapeutics, and its AI subsidiary, Open Medicine AI. For more information, visit www.lanternpharma.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements include, among other things, statements relating to: future events or our future financial performance; the expected market opportunity, user needs, platform roadmap, key future milestones, expected economics, and commercial model for the Open-Medicine AI platform; plans for the performance, benchmarking, and differentiation of the Open-Medicine AI platform; expectations relating to collaborations and partnerships; the planned evolution of the Open-Medicine AI platform beyond withZeta.ai to target broader disease areas, new modalities, and additional real-world drug development challenges; the planned development, value proposition and commercial potential of the Open-Medicine AI platform; and the potential advantages of the Open-Medicine AI platform in identifying drug candidates, accelerating drug development, and generating revenue through software licensing and subscription models.
Upcoming Open-Medicine AI Webinar - www.lanternpharma.com
Any statements that are not statements of historical fact (including, without limitation, statements that use words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “model,” “objective,” “aim,” “upcoming,” “should,” “will,” “would,” or the negative of these words or other similar expressions) should be considered forward-looking statements. There are a number of important factors that could cause our actual results to differ materially from those indicated by the forward-looking statements, such as (i) the risk that we may not be able to secure sufficient future funding when needed and as required to advance and support our existing and planned development programs and operations, (ii) the risk that our Open-Medicine AI commercialization efforts may not generate the anticipated revenue or achieve the expected market adoption, (iii) the risk that implementation of our development plans and new features for Open-Medicine AI may not be successful or may take longer than anticipated for development, completion, and release, (iv) the risk that no drug product based on our proprietary AI platforms has received FDA marketing approval or otherwise been incorporated into a commercial product, (v) the risk that benchmark or internal performance results for the Open-Medicine AI platform may not be indicative of performance in other settings or in use by third parties, (vi) the risk that ongoing partnership and collaborations discussions may not result in definitive agreements on acceptable terms or at all, and (vii) technical, scientific, regulatory, financial, competitive, and operational risks and those other factors set forth in the Risk Factors section in our Annual Report on Form 10-K for the year ended December 31, 2025, filed with the Securities and Exchange Commission on March 30, 2026.
You may access our Annual Report on Form 10-K for the year ended December 31, 2025 under the investor SEC filings tab of our website at www.lanternpharma.com or on the SEC’s website at www.sec.gov. Given these risks and uncertainties, we can give no assurances that our forward-looking statements will prove to be accurate, or that any other results or events projected or contemplated by our forward-looking statements will in fact occur, and we caution investors not to place undue reliance on these statements. All forward-looking statements in this press release represent our judgment as of the date hereof, and, except as otherwise required by law, we disclaim any obligation to update any forward-looking statements to conform the statement to actual results or changes in our expectations.
Media & Investor Contacts
Lantern Pharma — Investor Relations
Email: IR@lanternpharma.com
Phone: (972) 277-1136
Upcoming Open-Medicine AI Webinar - www.lanternpharma.com